This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (246)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Prostate Disease  • Oncology  • Prostate Cancer  • Pathology & Laboratory Medicine  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic

-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer

Mark A. Rubin, MD; Ming Zhou, MD,PhD; Saravana M. Dhanasekaran, PhD; Sooryanarayana Varambally, PhD; Terrence R. Barrette; Martin G. Sanda, MD; Kenneth J. Pienta, MD; Debashis Ghosh, PhD; Arul M. Chinnaiyan, MD,PhD

JAMA. 2002;287:1662-1670.

Context  Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens.

Objectives  To determine the expression and clinical utility of -methylacyl coenzyme A racemase (AMACR), a gene identified as being overexpressed in prostate cancer by global profiling strategies.

Design  Four gene expression data sets from independent DNA microarray analyses were examined to identify genes expressed in prostate cancer (n = 128 specimens). A lead candidate gene, AMACR, was validated at the transcript level by reverse transcriptase polymerase chain reaction (RT-PCR) and at the protein level by immunoblot and immunohistochemical analysis. AMACR levels were examined using prostate cancer tissue microarrays in 342 samples representing different stages of prostate cancer progression. Protein expression was characterized as negative (score = 1), weak (2), moderate (3), or strong (4). Clinical utility of AMACR was evaluated using 94 prostate needle biopsy specimens.

Main Outcome Measures  Messenger RNA transcript and protein levels of AMACR; sensitivity and specificity of AMACR as a tissue biomarker for prostate cancer in needle biopsy specimens.

Results  Three of 4 independent DNA microarray analyses (n = 128 specimens) revealed significant overexpression of AMACR in prostate cancer (P<.001). AMACR up-regulation in prostate cancer was confirmed by both RT-PCR and immunoblot analysis. Immunohistochemical analysis demonstrated an increased expression of AMACR in malignant prostate epithelia relative to benign epithelia. Tissue microarrays to assess AMACR expression in specimens consisting of benign prostate (n = 108 samples), atrophic prostate (n = 26), prostatic intraepithelial neoplasia (n = 75), localized prostate cancer (n = 116), and metastatic prostate cancer (n = 17) demonstrated mean AMACR protein staining intensity of 1.31 (95% confidence interval, 1.23-1.40), 2.33 (95% CI, 2.13-2.52), 2.67 (95% CI, 2.52-2.81), 3.20 (95% CI, 3.10-3.28), and 2.50 (95% CI, 2.20-2.80), respectively (P<.001). Pairwise comparisons demonstrated significant differences in staining intensity between clinically localized prostate cancer compared with benign prostate tissue, with mean expression scores of 3.2 and 1.3, respectively (mean difference, 1.9; 95% CI, 1.7-2.1; P<.001). Using moderate or strong staining intensity as positive (score = 3 or 4), evaluation of AMACR protein expression in 94 prostate needle biopsy specimens demonstrated 97% sensitivity and 100% specificity for detecting prostate cancer.

Conclusions  AMACR was shown to be overexpressed in prostate cancer using independent experimental methods and prostate cancer specimens. AMACR may be useful in the interpretation of prostate needle biopsy specimens that are diagnostically challenging.

Author Affiliations: Departments of Pathology (Drs Rubin, Zhou, Dhanasekaran, Varambally, and Chinnaiyan and Mr Barrette), Urology (Drs Rubin, Sanda, Pienta, and Chinnaiyan), Internal Medicine (Dr Pienta), and Biostatistics (Dr Ghosh) and Comprehensive Cancer Center (Drs Rubin, Sanda, Pienta, and Chinnaiyan), University of Michigan Medical School, Ann Arbor.

RELATED LETTER

-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer
Zhong Jiang, Bruce A. Woda, Ximing J. Yang, Mark A. Rubin, and Arul M. Chinnaiyan
JAMA. 2002;287(23):3080-3081.
EXTRACT | FULL TEXT  

RELATED ARTICLE

April 3, 2002
JAMA. 2002;287(13):1735-1736.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Histogenesis of Clear Cell Adenocarcinoma in the Urinary Tract: Evidence of Urothelial Origin
Sung et al.
Clin. Cancer Res. 2008;14:1947-1955.
ABSTRACT | FULL TEXT  

WDR19 Expression is Increased in Prostate Cancer Compared with Normal Cells, but Low-Intensity Expression in Cancers is Associated with Shorter Time to Biochemical Failures and Local Recurrence
Lin et al.
Clin. Cancer Res. 2008;14:1397-1406.
ABSTRACT | FULL TEXT  

A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer
Laxman et al.
Cancer Res. 2008;68:645-649.
ABSTRACT | FULL TEXT  

Higher Expression of the Androgen-Regulated Gene PSA/HK3 mRNA in Prostate Cancer Tissues Predicts Biochemical Recurrence-Free Survival
Sterbis et al.
Clin. Cancer Res. 2008;14:758-763.
ABSTRACT | FULL TEXT  

A Perspective on DNA Microarrays in Pathology Research and Practice
Pollack
Am. J. Pathol. 2007;171:375-385.
ABSTRACT | FULL TEXT  

Quantitative Fluorescence Imaging Analysis for Cancer Biomarker Discovery: Application to {beta}-Catenin in Archived Prostate Specimens
Huang et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1371-1381.
ABSTRACT | FULL TEXT  

Collagen XXIII Expression Is Associated with Prostate Cancer Recurrence and Distant Metastases
Banyard et al.
Clin. Cancer Res. 2007;13:2634-2642.
ABSTRACT | FULL TEXT  

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Shaffer et al.
Clin. Cancer Res. 2007;13:2023-2029.
ABSTRACT | FULL TEXT  

Diagnosis of adenocarcinoma in prostate needle biopsy tissue
Humphrey
J. Clin. Pathol. 2007;60:35-42.
ABSTRACT | FULL TEXT  

The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis.
D'Arcy et al.
Clin. Cancer Res. 2006;12:5978-5986.
ABSTRACT | FULL TEXT  

Isolation of human prostatic epithelial plasma membranes for proteomics using mirror image tissue banking of radical prostatectomy specimens.
Sircar et al.
Clin. Cancer Res. 2006;12:4178-4184.
ABSTRACT | FULL TEXT  

Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer
Febbo et al.
Clin. Cancer Res. 2006;12:152-158.
ABSTRACT | FULL TEXT  

Application of a priori established gene sets to discover biologically important differential expression in microarray data
Bild and Febbo
Proc. Natl. Acad. Sci. USA 2005;102:15278-15279.
FULL TEXT  

Autoantibody Signatures in Prostate Cancer
Wang et al.
NEJM 2005;353:1224-1235.
ABSTRACT | FULL TEXT  

Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells
Dimitroff et al.
Cancer Res. 2005;65:5750-5760.
ABSTRACT | FULL TEXT  

Molecular pathology of prostate cancer
Hughes et al.
J. Clin. Pathol. 2005;58:673-684.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl-CoA Racemase Protein Expression Is Associated with the Degree of Differentiation in Breast Cancer Using Quantitative Image Analysis
Witkiewicz et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1418-1423.
ABSTRACT | FULL TEXT  

Decreased {alpha}-Methylacyl CoA Racemase Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death
Rubin et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1424-1432.
ABSTRACT | FULL TEXT  

Multiclass cancer classification and biomarker discovery using GA-based algorithms
Liu et al.
Bioinformatics 2005;21:2691-2697.
ABSTRACT | FULL TEXT  

Reg IV: A Promising Marker of Hormone Refractory Metastatic Prostate Cancer
Gu et al.
Clin. Cancer Res. 2005;11:2237-2243.
ABSTRACT | FULL TEXT  

A Nonclassic CCAAT Enhancer Element Binding Protein Binding Site Contributes to {alpha}-Methylacyl-CoA Racemase Expression in Prostate Cancer
Zha and Isaacs
Mol Cancer Res 2005;3:110-118.
ABSTRACT | FULL TEXT  

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases: Lessons from a Rapid Autopsy Program
Shah et al.
Cancer Res. 2004;64:9209-9216.
ABSTRACT | FULL TEXT  

Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer: Genome-wide Gene-expression Profiles of Prostate Cancers and PINs
Ashida et al.
Cancer Res. 2004;64:5963-5972.
ABSTRACT | FULL TEXT  

Improved Biomarkers for Prostate Cancer: A Definite Need
Carter and Isaacs
JNCI J Natl Cancer Inst 2004;96:813-815.
FULL TEXT  

Humoral Immune Response to {alpha}-Methylacyl-CoA Racemase and Prostate Cancer
Sreekumar et al.
JNCI J Natl Cancer Inst 2004;96:834-843.
ABSTRACT | FULL TEXT  

RKIP Sensitizes Prostate and Breast Cancer Cells to Drug-induced Apoptosis
Chatterjee et al.
J. Biol. Chem. 2004;279:17515-17523.
ABSTRACT | FULL TEXT  

Elevated {alpha}-Methylacyl-CoA Racemase Enzymatic Activity in Prostate Cancer
Kumar-Sinha et al.
Am. J. Pathol. 2004;164:787-793.
ABSTRACT | FULL TEXT  

Quantitative Determination of Expression of the Prostate Cancer Protein {alpha}-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA): A Novel Paradigm for Automated and Continuous Biomarker Measurements
Rubin et al.
Am. J. Pathol. 2004;164:831-840.
ABSTRACT | FULL TEXT  

The Role of Metastasis-Associated Protein 1 in Prostate Cancer Progression
Hofer et al.
Cancer Res. 2004;64:825-829.
ABSTRACT | FULL TEXT  

Gene expression profiling identifies clinically relevant subtypes of prostate cancer
Lapointe et al.
Proc. Natl. Acad. Sci. USA 2004;101:811-816.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies
Evans
J. Clin. Pathol. 2003;56:892-897.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl-CoA Racemase as an Androgen-Independent Growth Modifier in Prostate Cancer
Zha et al.
Cancer Res. 2003;63:7365-7376.
ABSTRACT | FULL TEXT  

Branched Fatty Acids in Dairy and Beef Products Markedly Enhance {alpha}-Methylacyl-CoA Racemase Expression in Prostate Cancer Cells in Vitro
Mobley et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:775-783.
ABSTRACT | FULL TEXT  

Molecular biology of prostate cancer
Schulz et al.
Mol Hum Reprod 2003;9:437-448.
ABSTRACT | FULL TEXT  

Fatty Acid Synthase Expression Defines Distinct Molecular Signatures in Prostate Cancer
Rossi et al.
Mol Cancer Res 2003;1:707-715.
ABSTRACT | FULL TEXT  

Transcriptional Silencing of Zinc Finger Protein 185 Identified by Expression Profiling Is Associated with Prostate Cancer Progression
Vanaja et al.
Cancer Res. 2003;63:3877-3882.
ABSTRACT | FULL TEXT  

Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis
Fu et al.
JNCI J Natl Cancer Inst 2003;95:878-889.
ABSTRACT | FULL TEXT  

Expression Profiling Identifies a Novel {alpha}-Methylacyl-CoA Racemase Exon with Fumarate Hydratase Homology
Shen-Ong et al.
Cancer Res. 2003;63:3296-3301.
ABSTRACT | FULL TEXT  

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer
Rhodes et al.
JNCI J Natl Cancer Inst 2003;95:661-668.
ABSTRACT | FULL TEXT  

Gene Expression Patterns in Renal Cell Carcinoma Assessed by Complementary DNA Microarray
Higgins et al.
Am. J. Pathol. 2003;162:925-932.
ABSTRACT | FULL TEXT  

The Role of Calpain in the Proteolytic Cleavage of E-cadherin in Prostate and Mammary Epithelial Cells
Rios-Doria et al.
J. Biol. Chem. 2003;278:1372-1379.
ABSTRACT | FULL TEXT  

Use of High-Throughput DNA Microarrays to Identify Biomarkers for Bladder Cancer
Sanchez-Carbayo
Clin. Chem. 2003;49:23-31.
ABSTRACT | FULL TEXT  

Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression
Xin et al.
Am. J. Pathol. 2003;162:255-261.
ABSTRACT | FULL TEXT  

HEPSIN Inhibits Cell Growth/Invasion in Prostate Cancer Cells
Srikantan et al.
Cancer Res. 2002;62:6812-6816.
ABSTRACT | FULL TEXT  

Sequence Variants of {alpha}-Methylacyl-CoA Racemase Are Associated with Prostate Cancer Risk
Zheng et al.
Cancer Res. 2002;62:6485-6488.
ABSTRACT | FULL TEXT  

Changes in Differential Gene Expression because of Warm Ischemia Time of Radical Prostatectomy Specimens
Dash et al.
Am. J. Pathol. 2002;161:1743-1748.
ABSTRACT | FULL TEXT  

Distinct and Complementary Information Provided by Use of Tissue and DNA Microarrays in the Study of Breast Tumor Markers
Ginestier et al.
Am. J. Pathol. 2002;161:1223-1233.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl-CoA Racemase: Expression Levels of this Novel Cancer Biomarker Depend on Tumor Differentiation
Kuefer et al.
Am. J. Pathol. 2002;161:841-848.
ABSTRACT | FULL TEXT  

{alpha}-Methylacyl Coenzyme A Racemase as a Marker for Prostate Cancer
Jiang et al.
JAMA 2002;287:3080-3081.
FULL TEXT  

Basic Science and Translational Research in JAMA
Fontanarosa and DeAngelis
JAMA 2002;287:1728-1728.
FULL TEXT